NCT03385239 - Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

November 25, 2019

Study Completion Date

February 25, 2020

Conditions

HypertriglyceridemiaCardiovascular Diseases

Interventions

DRUG

ISIS 678354

ISIS 678354 solution for SC injection.

DRUG

Placebo

Sterile Normal Saline (0.9% NaCl).

Trial Locations (31)

13326

Clinical Site, Cooperstown

19446

Clinical Site, Lansdale

19803

Clinical Site, Wilmington

27262

Clinical Site, High Point

29651

Clinical Site, Greer

32216

Clinical Site, Jacksonville

33434

Clinical Site, Boca Raton

34652

Clinical Site, New Port Richey

40213

Clinical Site, Louisville

46321

Clinical Site, Munster

50010

Clinical Site, Ames

53215

Clinical Site, Milwaukee

66160

Clinical Site, Kansas City

72205

Clinical Site, Little Rock

77030

Clinical Site, Houston

86326

Clinical Site, Cottonwood

90807

Clinical Site, Long Beach

91763

Clinical Site, Montclair

93720

Clinical Site, Fresno

95608

Clinical Site, Carmichael

97239

Clinical Site, Portland

92037-7410

Clinical Site, La Jolla

02721

Clinical Site, Fall River

02906

Clinical Site, Providence

N1R 6V6

Clinical Site, Cambridge

P3E 5M4

Clinical Site, Greater Sudbury

J4Z 2K9

Clinical Site, Brossard

Unknown

Clinical Site, Chicoutimi

J8Y 6S8

Clinical Site, Gatineau

H1T 1C8

Clinical Site, Montreal

G1V 4W2

Clinical Site, Québec